Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension

While posaconazole prophylaxis decreases the risk of invasive fungal infection compared to fluconazole, low bioavailability of the oral-suspension formulation limits its efficacy. A new delayed-release tablet formulation demonstrated an improved pharmacokinetic profile in healthy volunteers. However...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Durani, Urshila, Tosh, Pritish K., Barreto, Jason N., Estes, Lynn L., Jannetto, Paul J., Tande, Aaron J.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2015
Sujets:
Clinical Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4505263/
https://ncbi.nlm.nih.gov/pubmed/26055378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00496-15
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires